63. 免疫性血小板減少症 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 575 / 薬物数 : 261 - (DrugBank : 64) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 142
薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
10-MG dose OF E5501 2G tablet
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 cyclodextrin oral solution
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 lipid-based oral
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501-P21% powder
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
Acetominophen
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
AKR-501, YM-477
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Alemtuzumab, rituximab
Hospital Universitario Dr. Jose E. Gonzalez
2008 Phase 2/Phase 3 NCT00749112 Mexico
ALL-trans-retinoid acid
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01668615 China
AMG 531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
Amgen
2007 Phase 3 NCT00603642 Japan
2007 Phase 1/Phase 2 NCT00515203 Australia;Canada;Spain;United States
2005 Phase 3 NCT00102336 United States
2005 Phase 3 NCT00102323 France;Netherlands;Spain;United States
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2005 Phase 3 EUCTR2004-000174-31-GB Spain;United Kingdom
2005 - EUCTR2004-000174-31-ES Spain;United Kingdom
2005 Phase 3 EUCTR2004-000173-65-GB Spain;United Kingdom
2005 - EUCTR2004-000173-65-ES Spain;United Kingdom
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2007-000638-37-IE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 3 EUCTR2004-000172-13-GB Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-DE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-CZ Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-BE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-AT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2007 Phase 2 EUCTR2007-003569-42-ES Spain
2007 - EUCTR2006-003700-18-PT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
AMG531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2004-000172-13-IT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
Amifostine
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
Aminophylline
Department of Hematology, The First Affiliated Hospital of Soochow University
2017 - ChiCTR-ONC-17013230 China
Amoxicillin
Assiut University
2020 Phase 4 NCT03172676 Egypt
Amoxicillin hydrate
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
ANTI-CD38 antibody injection
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06168851 China
ANTI-CD40L
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-CD40ldab
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-D
University of Aarhus
2004 Phase 2 NCT00128882 Denmark
ARGX-113
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx
2017 Phase 2 NCT03102593 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Atorvastatin 10MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 20MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 40 MG oral tablet + N-acetylcysteine 400 MG oral tablet
Hospital Civil de Guadalajara
2018 Early Phase 1 NCT05551624 Mexico
Atra
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Shandong University
2013 Phase 3 NCT01882127 China
Avatrombopag
Eisai Inc.
2012 Phase 3 NCT01433978 United States
Eisai Limited
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06281327 China
Shandong University
2021 - NCT04949009 China
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
Avatrombopag maleate
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Avatrombopag tablets
Eisai Inc.
2007 Phase 2 NCT00625443 United States
2007 Phase 2 NCT00441090 United States
Azathioprine
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
B02bx05
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Belimumab
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
BI 655064
Boehringer Ingelheim
2013 Phase 1 NCT02009761 United States
Biological: M254
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Blisibimod
Anthera Pharmaceuticals
2015 Phase 2/Phase 3 NCT01609452 -
BMS-986004
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
BMS-986004 1500 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 225 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 675 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 75 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
Bortezomib
Shandong University
2018 Phase 3 NCT03443570 China
BT595
Biotest
2016 Phase 3 NCT02859909 Bulgaria;Czechia;Germany;Hungary;Serbia;Spain
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
Caffeic acid tablets
Shandong University
2015 Phase 4 NCT02556814 China
Caplacizumab
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
CAR-T cells
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
2024 Phase 1/Phase 2 NCT06352281 China
CC312
CytoCares Inc
2024 Early Phase 1 NCT06888960 China
CD4-IGG
Genentech, Inc.
1997 Phase 1 NCT00002250 United States
Clarithromycin
Assiut University
2020 Phase 4 NCT03172676 Egypt
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
CM313 injection
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06199089 China
2023 Phase 2 NCT05694767 China
Keymed Biosciences Co.Ltd
2024 Phase 2 NCT06594146 China
CM336 injection
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06799611 China
Collection OF biological samples
University Hospital, Bordeaux
2011 Phase 3 NCT04070599 -
Combination OF rituximab with subcutaneous belimumab
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT05338190 France
Conventional
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Corticosteroids
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Novartis Pharmaceuticals
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Corticosteroids combined with immunoglobulin and romiplostim
Wuhan Union Hospital, China
2024 Phase 2 NCT06686927 China
CSA
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Cyclosporin
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Cyclosporine
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
2020 Phase 4 ChiCTR2000030603 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
Danazol
Second Affiliated Hospital of Dalian Medical University
2018 - ChiCTR1800016177 China
Daratumumab
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
the First Affiliated Hospital of University of Science and Technology of China
2024 Phase 0 ChiCTR2400091558 China
Daratumumab injection
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06838962 China
2022 Phase 2 NCT05562882 China
Darzalex
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Decitabine
Shandong University
2018 Phase 3 NCT03252457 China
Desametasone 40MG
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
Dexamethasone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
Peking University People's Hospital
2023 Phase 2 NCT06176235 China
Shandong University
2021 Phase 2 NCT05023915 China
2021 Phase 2/Phase 3 NCT03692754 China
2019 Phase 4 NCT03998982 China
2018 Phase 3 NCT03252457 China
2015 Phase 4 NCT02642380 China
2015 Phase 4 NCT02556814 China
2013 Phase 3 NCT01882127 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2010 Phase 4 NCT01356511 China
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
University Hospital, Macau
2015 - ChiCTR1900021211 China
Dexamethasone abcur
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Dexamethasone and rituximab
Copenhagen University Hospital at Herlev
2004 Phase 3 NCT00909077 Denmark
Dexamethasone combined with romiplostim N01
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06658834 China
Dexamethasone monotherapy
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06658834 China
Dexamethasone oral
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
Dexamethasone palmitate
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 -
Dexamethasone USP micronized
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Diammonium glycyrrhizinate enteric-coated capsule
Shandong University
2021 Phase 2 NCT05023915 China
Difenidramina cloridrato
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Doptelet 20 MG FILM-coated tablets
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Doxil
Hematology and Oncology Specialists
2001 Phase 2 NCT00107913 United States
Dyphenhydramine hydrochloride
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
E5501
Eisai Inc.
2011 Phase 1 NCT01437384 United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
E5501 40 MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40 MG 2 X 20-MG tablets, orally, with food
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
Efgartigimod
ARGENX BV
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
argenx
2020 Phase 3 NCT04274452 United States
2020 Phase 3 NCT04225156 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 NCT04188379 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod alfa
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Efgartigimod alpha
argenx BVBA
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod IV
argenx
2024 Phase 3 NCT06544499 Austria;Bulgaria;Ireland;Italy;Poland;Spain;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx
2021 Phase 3 NCT04812925 Argentina;Australia;Bulgaria;Chile;China;Georgia;Greece;Ireland;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;South Africa;Thailand;Tunisia;Turkey;United Kingdom;United States
2020 Phase 3 NCT04687072 Argentina;Australia;Bulgaria;Chile;China;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Eltrombopag
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan
2016 Phase 3 NCT02877212 Pakistan
Eisai Inc.
2012 Phase 3 NCT01433978 United States
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline
2012 Phase 3 NCT01520909 Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2010 - NCT01439321 -
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2009 - NCT01236014 -
2009 Phase 2 NCT00908037 Canada;France;Netherlands;Spain;United Kingdom;United States
2007 Phase 2 NCT00424177 Australia;Canada;Germany;India;Korea, Republic of;Netherlands;Russian Federation;Spain;Tunisia;United Kingdom;United States
2006 Phase 3 NCT00370331 Austria;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 Phase 2 NCT02402998 Italy
2016 - NCT02298075 Italy
Humanity & Health Medical Group Limited
2018 Phase 2 NCT03830749 Hong Kong
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 4 NCT05583838 China
Jikei University school of Medicine
2011 - JPRN-UMIN000006150 Japan
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Novartis Pharmaceuticals
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 NCT03524612 Austria;Brazil;Chile;France;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
2010 - NCT01416311 -
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2020 - NCT04214951 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
University Hospital, Macau
2015 - ChiCTR1900021211 China
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
Yunfeng Cheng
2024 - NCT06479291 China;Hong Kong;Macau
Eltrombopag 25 MG
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
Eltrombopag and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2012 Phase 2 NCT01652599 Mexico
Eltrombopag and romiplastim
Assiut University
2023 - NCT06137105 -
Eltrombopag combining rituximab
Institute of Hematology & Blood Diseases Hospital
2020 Phase 4 NCT04518475 China
Eltrombopag olamine
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
Eltrombopag olamine, revolade, promacta
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Eltrombopag oral tablets
GlaxoSmithKline
2008 Phase 3 NCT00828750 Japan
Eltrombopag plus diacerein
Qilu Hospital of Shandong University
2020 Phase 2 NCT04917679 China
ESG206
Shanghai Escugen Biotechnology Co., Ltd
2025 Phase 1/Phase 2 NCT06853444 China
Estimation OF serum level OF IL17
Sohag University
2022 - NCT05371743 Egypt
Estimation OF serum level OF IL2
Sohag University
2022 - NCT05371743 Egypt
Ethanolamine
West China Hospital,Sichuan University
2022 Phase 2 ChiCTR2200065074 China
Fecal microbiota transplantation
Chinese University of Hong Kong
2019 - NCT04014413 Hong Kong
Fostamatinib
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2023 - NCT06071520 Spain
Kissei Pharmaceutical Co., Ltd.
2023 - NCT06757257 Japan
2019 Phase 3 JPRN-jRCT2080224916 Japan
Fostamatinib disodium
Rigel Pharmaceuticals
2015 Phase 3 NCT02076412 Austria;Bulgaria;Czech Republic;Czechia;Germany;Norway;Poland;Romania;Spain;United States
2014 Phase 3 NCT02077192 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Hungary;Italy;Netherlands;Norway;Poland;Romania;Spain;United Kingdom;United States
2014 Phase 3 NCT02076399 Australia;Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Fostamatinib disodium / R935788
Rigel Pharmaceuticals
2007 Phase 2 NCT00706342 United States
Fostamatinib disodium 100 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium 150 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium tablets
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Gammaplex
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Gammaplex, intravenous immunoglobulin
Bio Products Laboratory
2007 Phase 3 NCT00504075 Argentina;India;United States
Global DNA methylation will BE quantified IN THE DNA samples BY colorimetry
Assiut University
2019 - NCT04100876 -
Glycyrrhetinic acid
Shandong University
2019 Phase 4 NCT03998982 China
Glycyrrhiza
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
GMA161
Genzyme, a Sanofi Company
2005 Phase 1 NCT00244257 United States
GNR-069
AO GENERIUM
2022 Phase 3 NCT05492409 Russian Federation
2021 Phase 3 NCT05220878 Russian Federation
H. pylori triple therapy
Federal University of São Paulo
2008 Phase 2/Phase 3 NCT01730352 Brazil
HBM9161 dose A
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
HBM9161 dose B
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
Healthy controls
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Herombopag
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 3 NCT05685420 -
Herombopag olamine tablets
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06838949 China
Hetrombopag
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 3 NCT04737850 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
West China Hospital, Sichuan University
2025 - ChiCTR2500096457 China
Wuhan Union Hospital, China
2022 - NCT05333861 China
Hetrombopag 5MG PO QD
Shandong University
2023 Phase 2 NCT05943691 China
Hetrombopag olamine
Jiangsu HengRui Medicine Co., Ltd.
2015 Phase 1 NCT02614846 China
2014 Phase 1 NCT02403440 China
High dose dexamethasone pulses
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
HIGH-dose dexamethasone
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Shandong University
2023 Phase 2 NCT05943691 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
Higher dose OF rituximab
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
HMPL-523
Hutchison Medipharma Limited
2021 Phase 3 NCT05029635 China
Hutchmed
2024 Phase 1 NCT06291415 Australia;Germany;Norway;Spain;United States
Huaiqihuang granule
Qidong Gaitianli Medicines Co., Ltd
2017 Phase 4 NCT03201848 China
Human immunoglobulin
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Human immunoglobulin G
Octapharma AG
2006 - EUCTR2005-003552-35-DE Czech Republic;France;Germany
2006 - EUCTR2005-003552-35-AT Austria;Czech Republic;France;Germany
Human normal immunoglobulin
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Human normal immunoglobulin FOR intravenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Human normal immunoglobulin FOR intrvenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Humax-CD38
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Hydroxychloroquine
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
Hydroxychloroquine oral tablet
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
2024 - NCT06479304 China;Hong Kong;Macau
2024 - NCT06479291 China;Hong Kong;Macau
Hypersialylated immunoglobulin
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
I10E
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Ianalumab
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2023 Phase 2 NCT05885555 Argentina;Australia;China;Czechia;France;Germany;Italy;Korea, Republic of;Malaysia;Poland;Spain;Turkey;United Kingdom;United States
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2061220095 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;China;Czech Republic;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
IG vena 100 ML vial
Kedrion SpA
2013 - EUCTR2013-000961-36-IT Italy
IG vena 50 G/L solution FOR infusion 100 ML vial + infusion SET
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy
IGG next generation
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
IGIV3I grifols
Grifols Biologicals Inc.
2008 Phase 3 NCT00511147 Canada;India;Puerto Rico;United States
Instituto Grifols, S.A.
2008 Phase 3 NCT00699140 Russian Federation;Spain;United Kingdom
Igpro10
CSL Behring
2011 Phase 4 NCT01390649 Bulgaria;Poland;Romania;Serbia
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Immune globulin intravenous
Baxalta now part of Shire
2002 Phase 3 NCT00157079 United States
Immune globulin intravenous (human), 10% triple virally reduced solution
Baxalta now part of Shire
2003 Phase 2 NCT00162006 Czech Republic;Czechia;Germany;Hungary;Poland
Immunglobulin
Octapharma AG
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulin
CSL Behring
2004 Phase 3 NCT00168038 Germany;Italy;Poland;Russian Federation;Switzerland;Ukraine;United Kingdom
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Immunoglobulin G
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulina umana normale
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
Inactivated trivalent influenza vaccine
Neufeld, Ellis J, MD, PhD
2004 - NCT01713855 United States
Interleukin 2
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT01988506 France
Intravenous immunoglobulin (ivig), 10% solution FOR infusion
Biopharma Plasma LLC
2022 Phase 3 NCT05422365 Ukraine
Ivig
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Ivig infusion
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
IVIG-L
Sanquin
2001 Phase 3 NCT00151840 Poland
L01fc01
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
Lansoprazole, clarithromycin, amoxycillin
Mahidol University
2006 Phase 4 NCT00467571 Thailand
LGD-4665
GlaxoSmithKline
2008 Phase 2 NCT00621894 United States
LIV-gamma SN INJ.
SK Plasma Co., Ltd.
2019 Phase 3 NCT05566990 Korea, Republic of
Lusutrombopag
Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
2024 Phase 4 ChiCTR2400080388 China
Lusutrombopag oral tablet
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06287567 China
M254
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
Mabthera
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2010 Phase 3 EUCTR2005-005918-20-GB France;Sweden;United Kingdom
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
University Hospital, Toulouse
2009 - NCT00960713 France
MabthéRA
Assistance Publique - Hôpitaux de Paris
2003 Phase 2 NCT00225875 France
Medical standard OF care FOR ITP
Amgen
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Methylprednisolone
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
2016 Phase 4 study ChiCTR-IIR-16008994 China
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Methylprednisolone and ivig
The Hospital for Sick Children
2005 Phase 3 NCT00376077 Canada
Metilprednisolone
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Metronidazole
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Mezagitamab
Takeda
2025 Phase 3 NCT06948318 -
2025 Phase 3 NCT06722235 China;Japan
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Montelukast
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Mycophenolate mofetil
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
Nanogam
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Neofordex
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
Newgam
Octapharma
2011 Phase 3 NCT01349790 Germany
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Nicotinamide adenine dinucleotid/nicotinamide mononucleotide
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 1/Phase 2 NCT06776510 China
NK cells
Changzhou No.2 People's Hospital
2024 Early Phase 1 NCT06337474 China
Nplate
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
Nplate 500 microgramos polvo para solucióN inyectable
Amgen Inc
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
Obinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06094881 China
2023 Phase 2 NCT05995054 China
Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
2023 Phase 3 NCT06004856 China
2022 Phase 2 NCT05232149 China
Shandong University
2021 Phase 2 NCT05020288 -
Paracetamolo
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
PF-06755347 intravenous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous ITP
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06835375
Pfizer
2022 Phase 2 NCT05070845 Australia;Canada;Czechia;Hungary;Poland;United Kingdom;United States
Pfizer Inc.
2022 Phase 2 EUCTR2021-002897-19-HU Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
2022 Phase 2 EUCTR2021-002897-19-CZ Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
PG2
PhytoHealth Corporation
2008 Phase 2 NCT00860600 Taiwan
Plasma RNA isolation, qpcr analysis OF micro RNA
Sohag University
2022 - NCT05371743 Egypt
PN20
Chongqing Peg-Bio Biopharm Co., Ltd.
2022 Phase 1 NCT06523088 China
PN20 treatment
Chongqing Peg-Bio Biopharm Co., Ltd.
2025 Phase 1 NCT06880081 China
Povetacicept
Alpine Immune Sciences, Inc.
2023 Phase 1/Phase 2 NCT05757570 Australia;Austria;Canada;Germany;Italy;Norway;Spain;Turkey;United Kingdom;United States
Prednisolone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
Prednisone
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
2013 - ChiCTR-TRC-13003602 China
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Huizhou Municipal Central Hospital
2022 Phase 4 ChiCTR2100053452 China
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
Mayo Clinic
2007 Phase 0 NCT00486421 United States
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Shandong University
2010 Phase 4 NCT01356511 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
Prednisone acetate
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Prednisone tablet
Yunfeng Cheng
2024 - NCT06479304 China;Hong Kong;Macau
Privigen
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
PRN1008
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
PRN1008 100 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 300 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 400 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
ProteíNA recombinante estimulante DE LA megacariopoyesis
Amgen Inc.
2007 Phase 2 EUCTR2007-003569-42-ES Spain
Proton pump inhibitor 1 MG/KG/DAY IN 2 divided doses 1 month
Assiut University
2020 Phase 4 NCT03172676 Egypt
PRTX-100
Protalex, Inc.
2007 Phase 1 NCT00571467 Australia;New Zealand
QL0911
Qilu Pharmaceutical Co., Ltd.
2019 Phase 3 NCT05621330 China
Quality-OF-life assessment
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
R788
Kissei Pharmaceutical Co., Ltd.
2019 Phase 3 NCT04132050 Japan
R935788
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Rapamycin
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01672151 China
Recombinant human thrombopoietin
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Peking University People's Hospital
2020 - NCT04214951 China
Shandong University
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Relovade
GlaxoSmithKline Research and Development Ltd
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
Revolade
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Revolade 25 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade 50 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade, promacta
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Rhtpo
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 4 NCT05583838 China
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
Peking Union Medical College
2011 Phase 3 NCT01805648 China
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Shandong University
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Rhtpo IN combination with rituximab
Ming Hou
2009 Phase 3 NCT01506414 China
Rilzabrutinib
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 2 NCT03395210 Australia;Bulgaria;Canada;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Rituxan
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
New York Medical College
2021 Phase 1 NCT04323748 United States
University Hospital, Toulouse
2009 - NCT00960713 France
Rituxan, cyclophosphamide, vincristine, prednisone
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
Rituximab
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR1900027748 China
Hamilton Health Sciences Corporation
2006 Phase 2 NCT00372892 Canada
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
2005 Phase 3 NCT00770562 Italy
Institute of Hematology & Blood Diseases Hospital, China
2012 - NCT01719692 China
Keio University School of Medicine , Yoshitaka miyakawa
2011 Phase 3 JPRN-jRCT1091220070 Japan
Mayo Clinic
2007 Phase 0 NCT00486421 United States
Neufeld, Ellis J, MD, PhD
2003 Phase 1/Phase 2 NCT01713738 United States
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Shandong University
2018 Phase 3 NCT03443570 China
2012 Phase 3 NCT01734057 China
2011 Phase 3 NCT01525836 China
2010 Phase 4 NCT03258866 China
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
University Hospital, Toulouse
2009 - NCT00960713 France
University of Alabama at Birmingham
2000 Phase 2 NCT00005652 United States
Weill Medical College of Cornell University
2004 Phase 2 NCT00161564 United States
Rituximab and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2010 Phase 2 NCT01107951 Mexico
Romiplostim
Amgen
2012 Phase 3 NCT01444417 Australia;Canada;United States
2010 Phase 2 NCT01143038 Australia;Czech Republic;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
2009 Phase 3 NCT01071954 Australia;Canada;Spain;United States
2009 Phase 4 NCT00907478 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;United States
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2005 Phase 3 NCT00508820 Australia;Austria;Belgium;Canada;Czech Republic;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom;United States
2004 Phase 3 NCT00116688 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2002 Phase 1/Phase 2 NCT00117143 -
2002 Phase 2 NCT00111475 -
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
GlaxoSmithKline
2010 - NCT01439321 -
2009 - NCT01236014 -
Qilu Hospital of Shandong University
2024 Phase 4 ChiCTR2400091685 China
University Hospital, Basel, Switzerland
2016 Phase 4 NCT02760251 Switzerland
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Romiplostim plus dexamethasone
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 3 NCT05325593 Spain
Romiplostin
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 - NCT02298075 Italy
Rozanolixizumab
Sugihara Kazuhiro
2021 Phase 3 JPRN-jRCT2031210245 Austria;Belgium;Bulgaria;Canada;China;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea;Poland;Republic of Moldova;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Biopharma SRL
2021 Phase 3 NCT04596995 China;Georgia;Germany;Hungary;Italy;Japan;Moldova, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04224688 Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04200456 Austria;Belgium;Bulgaria;Croatia;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-jRCT2080225255 Asia except Japan;Europe;Japan;North America
SAR444671
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
SB-497115
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
SB-497115-GR
GLAXO SMITHKLINE
2006 - EUCTR2004-000367-98-IT Denmark;Estonia;Germany;Ireland;Italy;Latvia;Spain;Sweden
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Limited
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
SB-497115-GR 12.5MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 25MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 50 MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB497115
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2005 Phase 2 NCT00102739 Australia;Brazil;Canada;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-LV Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-IE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-GB Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-ES Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-DE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline S.A.
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Serum interleukin 10 level
Sohag University
2023 - NCT05835050 Egypt
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States
Department of Hematology, Xiniao Hospital
2017 - ChiCTR-ONC-17012126 China
SM101
SuppreMol GmbH
2010 Phase 1;Phase 2 EUCTR2009-014842-28-BE Belgium;Germany;Poland
SM101 20MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
SM101 5MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
Standard therapy (without eltrombopag): HD-DXM
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Staphylococcal protein A
Protalex, Inc.
2007 Phase 1 NCT00571467 Australia;New Zealand
Steroids
Safaa AA Khaled
2019 - NCT04113915 -
STSA-1301 subcutaneous injection
Jiangsu BioJeTay Biotechnology Co., Ltd.
2025 Phase 1/Phase 2 NCT06929299 China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
2023 Phase 1 NCT06148389 China
SYM001
Symphogen A/S
2010 Phase 2 EUCTR2007-006081-15-GB Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2010 Phase 2 EUCTR2007-006081-15-BE Belgium;Germany;Spain;United Kingdom
2008 Phase 2 NCT00718692 Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2008 - EUCTR2007-006081-15-ES Belgium;Germany;Spain;United Kingdom
2008 - EUCTR2007-006081-15-DE Belgium;Germany;Spain;United Kingdom
TAK-079
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Takeda
2020 Phase 2 NCT04278924 Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Telitacicept
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
Teriflunomide
Peking University People's Hospital
2023 Phase 2 NCT06176235 China
Thrombopoietin
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
TPO
Peking University People's Hospital
2020 - NCT04214951 China
Shenyang Sunshine Pharmaceutical Co., LTD.
2016 Phase 4 NCT04089267 China
TPO-RA
Institute of Hematology & Blood Diseases Hospital, China
2021 - NCT04890041 China
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
TPO-RAS combining ANTI-CD 20 monoclonal antibody
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 4 NCT05718856 China
TQB3473 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025 Phase 3 NCT06900920 China
Treatment : H. pylori eradication
Seoul National University Hospital
2017 Phase 3 NCT03177629 Korea, Republic of
Tretinoin
The First Affiliated Hospital of Xinjiang Medical University
2025 - ChiCTR2500099739 China
Triple therapy
Safaa AA Khaled
2019 - NCT04113915 -
Tysabri
Sahlgrenska University Hospital
2009 Phase 1;Phase 2 EUCTR2008-005871-92-SE Sweden
UCB7665
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02718716 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SPRL
2017 Phase 2 EUCTR2015-003984-12-LT Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2017 Phase 2 EUCTR2015-003984-12-BG Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-PL Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-ES Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-DE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-BE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SRL
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2016 Phase 2 EUCTR2015-003984-12-IT Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
VAY736
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Veltuzumab
Gilead Sciences
2007 Phase 1/Phase 2 NCT00547066 United States
Vinblastine
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
VIT D
Mansoura University
2023 Early Phase 1 NCT06073925 -
VON willebrand factor
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Vonoprazan
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Water
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Zanubrutinib
He'nan Cancer Hospital
2022 Phase 4 ChiCTR2200060868 China
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2022 Phase 2 NCT05279872 China
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
Zuberitamab
Union hospital tongji medical college huazhong university of science and technology
2021 Phase 2 ChiCTR2100050513 China
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 cyclodextrin oral solution
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501 lipid-based oral
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
10-MG dose OF E5501-P21% powder
Eisai Inc.
2012 Phase 1 NCT01549054 United Kingdom
Acetominophen
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
AKR-501, YM-477
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Alemtuzumab, rituximab
Hospital Universitario Dr. Jose E. Gonzalez
2008 Phase 2/Phase 3 NCT00749112 Mexico
ALL-trans-retinoid acid
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01668615 China
AMG 531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
Amgen
2007 Phase 3 NCT00603642 Japan
2007 Phase 1/Phase 2 NCT00515203 Australia;Canada;Spain;United States
2005 Phase 3 NCT00102336 United States
2005 Phase 3 NCT00102323 France;Netherlands;Spain;United States
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2005 Phase 3 EUCTR2004-000174-31-GB Spain;United Kingdom
2005 - EUCTR2004-000174-31-ES Spain;United Kingdom
2005 Phase 3 EUCTR2004-000173-65-GB Spain;United Kingdom
2005 - EUCTR2004-000173-65-ES Spain;United Kingdom
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2007-000638-37-IE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 Phase 3 EUCTR2004-000172-13-GB Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-DE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-CZ Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-BE Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2008 - EUCTR2004-000172-13-AT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
2007 Phase 2 EUCTR2007-003569-42-ES Spain
2007 - EUCTR2006-003700-18-PT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-NL Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-GB Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-FR Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-DE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-CZ Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 Phase 3 EUCTR2006-003700-18-BE Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
2007 - EUCTR2006-003700-18-AT Austria;Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;United Kingdom
AMG531
AMGEN S.P.A.
2008 - EUCTR2007-000638-37-IT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2004-000172-13-IT Austria;Belgium;Czech Republic;Germany;Italy;United Kingdom
Amifostine
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
Aminophylline
Department of Hematology, The First Affiliated Hospital of Soochow University
2017 - ChiCTR-ONC-17013230 China
Amoxicillin
Assiut University
2020 Phase 4 NCT03172676 Egypt
Amoxicillin hydrate
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
ANTI-CD38 antibody injection
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06168851 China
ANTI-CD40L
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-CD40ldab
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
ANTI-D
University of Aarhus
2004 Phase 2 NCT00128882 Denmark
ARGX-113
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
2017 Phase 2 EUCTR2016-003038-26-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx
2017 Phase 2 NCT03102593 Austria;Belgium;Czech Republic;Czechia;France;Germany;Hungary;Poland;Spain;Ukraine;United Kingdom
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Atorvastatin 10MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 20MG
Shandong University
2021 Phase 2/Phase 3 NCT03692754 China
Atorvastatin 40 MG oral tablet + N-acetylcysteine 400 MG oral tablet
Hospital Civil de Guadalajara
2018 Early Phase 1 NCT05551624 Mexico
Atra
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Shandong University
2013 Phase 3 NCT01882127 China
Avatrombopag
Eisai Inc.
2012 Phase 3 NCT01433978 United States
Eisai Limited
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06281327 China
Shandong University
2021 - NCT04949009 China
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
Avatrombopag maleate
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Avatrombopag tablets
Eisai Inc.
2007 Phase 2 NCT00625443 United States
2007 Phase 2 NCT00441090 United States
Azathioprine
The Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR2000030603 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
B02bx05
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Belimumab
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
BI 655064
Boehringer Ingelheim
2013 Phase 1 NCT02009761 United States
Biological: M254
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Blisibimod
Anthera Pharmaceuticals
2015 Phase 2/Phase 3 NCT01609452 -
BMS-986004
Bristol-Myers Squibb International Corporation
2015 Phase 2 EUCTR2014-001429-33-PL Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United States
2014 Phase 2 EUCTR2014-001429-33-GB Canada;Poland;United Kingdom;United States
BMS-986004 1500 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 225 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 675 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
BMS-986004 75 MG IV
Bristol-Myers Squibb
2014 Phase 1/Phase 2 NCT02273960 Australia;Canada;Georgia;Moldova, Republic of;Poland;Russian Federation;United Kingdom;United States
Bortezomib
Shandong University
2018 Phase 3 NCT03443570 China
BT595
Biotest
2016 Phase 3 NCT02859909 Bulgaria;Czechia;Germany;Hungary;Serbia;Spain
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
Caffeic acid tablets
Shandong University
2015 Phase 4 NCT02556814 China
Caplacizumab
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
CAR-T cells
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
2024 Phase 1/Phase 2 NCT06352281 China
CC312
CytoCares Inc
2024 Early Phase 1 NCT06888960 China
CD4-IGG
Genentech, Inc.
1997 Phase 1 NCT00002250 United States
Clarithromycin
Assiut University
2020 Phase 4 NCT03172676 Egypt
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
CM313 injection
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06199089 China
2023 Phase 2 NCT05694767 China
Keymed Biosciences Co.Ltd
2024 Phase 2 NCT06594146 China
CM336 injection
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06799611 China
Collection OF biological samples
University Hospital, Bordeaux
2011 Phase 3 NCT04070599 -
Combination OF rituximab with subcutaneous belimumab
Assistance Publique - Hôpitaux de Paris
2022 Phase 3 NCT05338190 France
Conventional
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Corticosteroids
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Novartis Pharmaceuticals
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Corticosteroids combined with immunoglobulin and romiplostim
Wuhan Union Hospital, China
2024 Phase 2 NCT06686927 China
CSA
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Cyclosporin
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
2018 - ChiCTR-OON-17014165 China
Cyclosporine
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2022 - ChiCTR2200058433 China
2020 Phase 4 ChiCTR2000030603 China
the Second Affiliated Hospital of Kunming Medical University
2019 - ChiCTR1900027753 China
Danazol
Second Affiliated Hospital of Dalian Medical University
2018 - ChiCTR1800016177 China
Daratumumab
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
the First Affiliated Hospital of University of Science and Technology of China
2024 Phase 0 ChiCTR2400091558 China
Daratumumab injection
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06838962 China
2022 Phase 2 NCT05562882 China
Darzalex
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Decitabine
Shandong University
2018 Phase 3 NCT03252457 China
Desametasone 40MG
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
Dexamethasone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Hoffmann-La Roche
2005 Phase 3 NCT00770562 Italy
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
Peking University People's Hospital
2023 Phase 2 NCT06176235 China
Shandong University
2021 Phase 2 NCT05023915 China
2021 Phase 2/Phase 3 NCT03692754 China
2019 Phase 4 NCT03998982 China
2018 Phase 3 NCT03252457 China
2015 Phase 4 NCT02642380 China
2015 Phase 4 NCT02556814 China
2013 Phase 3 NCT01882127 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2010 Phase 4 NCT01356511 China
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
University Hospital, Macau
2015 - ChiCTR1900021211 China
Dexamethasone abcur
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Dexamethasone and rituximab
Copenhagen University Hospital at Herlev
2004 Phase 3 NCT00909077 Denmark
Dexamethasone combined with romiplostim N01
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06658834 China
Dexamethasone monotherapy
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06658834 China
Dexamethasone oral
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
Dexamethasone palmitate
Nakayama Takayuki
2019 Phase 1 JPRN-jRCTs041190069 -
Dexamethasone USP micronized
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Diammonium glycyrrhizinate enteric-coated capsule
Shandong University
2021 Phase 2 NCT05023915 China
Difenidramina cloridrato
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Doptelet 20 MG FILM-coated tablets
Dova Pharmaceuticals, Inc.
2020 Phase 3 EUCTR2020-003232-24-FR Czech Republic;France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Sobi, Inc.
2021 Phase 3 EUCTR2020-003232-24-DE France;Germany;Hungary;Poland;Russian Federation;Türkiye;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-PL France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-003232-24-HU France;Germany;Hungary;Poland;Russian Federation;Turkey;Ukraine;United Kingdom;United States
Doxil
Hematology and Oncology Specialists
2001 Phase 2 NCT00107913 United States
Dyphenhydramine hydrochloride
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
E5501
Eisai Inc.
2011 Phase 1 NCT01437384 United States
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000830-12-PL Austria;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-NL Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2012 - EUCTR2011-000830-12-GR Australia;Belgium;Bulgaria;China;Czech Republic;Greece;Hong Kong;Netherlands;New Zealand;Poland;Romania;Singapore;Slovakia;South Africa;Ukraine
2012 Phase 3 EUCTR2011-000830-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Greece;Netherlands;New Zealand;Poland;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-SK Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BG Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
2011 Phase 3 EUCTR2011-000830-12-BE Australia;Belgium;Bulgaria;China;Croatia;Czech Republic;Greece;Hong Kong;Hungary;Netherlands;New Zealand;Poland;Portugal;Romania;Singapore;Slovakia;South Africa;Ukraine
E5501 40 MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40 MG 2 X 20-MG tablets, orally, with food
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
E5501 40MG 2 X 20-MG tablets, orally, fasted
Eisai Inc.
2011 Phase 1 NCT01327872 Netherlands
Efgartigimod
ARGENX BV
2020 Phase 3 EUCTR2019-002101-21-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-IT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Argenx BVBA
2019 Phase 2 EUCTR2019-000361-21-GB Hungary;Spain;Ukraine;United Kingdom
argenx
2020 Phase 3 NCT04274452 United States
2020 Phase 3 NCT04225156 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 NCT04188379 Austria;Belgium;Bulgaria;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BV
2021 Phase 3 EUCTR2019-002101-21-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-CZ Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BG Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-GB Austria;Belgium;Bulgaria;Czech Republic;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod alfa
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Gandini Domenica
2022 Phase 3 JPRN-jRCT2071210087 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Korea;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
2021 Phase 3 JPRN-jRCT2071210025 Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Republic of Latvia;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BVBA
2020 Phase 3 EUCTR2019-002101-21-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002101-21-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-PL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-FR Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-CZ Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-BE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-NL Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-HU Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2019 Phase 3 EUCTR2019-002100-41-ES Austria;Belgium;Bulgaria;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Ukraine;United Kingdom;United States
Efgartigimod alpha
argenx BVBA
2020 Phase 3 EUCTR2019-002100-41-DE Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-002100-41-AT Austria;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Hungary;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
Efgartigimod IV
argenx
2024 Phase 3 NCT06544499 Austria;Bulgaria;Ireland;Italy;Poland;Spain;United Kingdom;United States
Efgartigimod PH20 SC
ARGENX BV
2021 Phase 3 EUCTR2020-004033-20-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx
2021 Phase 3 NCT04812925 Argentina;Australia;Bulgaria;Chile;China;Georgia;Greece;Ireland;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;South Africa;Thailand;Tunisia;Turkey;United Kingdom;United States
2020 Phase 3 NCT04687072 Argentina;Australia;Bulgaria;Chile;China;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
argenx BV
2022 Phase 3 EUCTR2020-004032-21-DK Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004033-20-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-RO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-PT Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-NO Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-IE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-FR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-ES Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Türkiye;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-DE Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
2021 Phase 3 EUCTR2020-004032-21-BG Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
- Phase 3 EUCTR2020-004032-21-GR Argentina;Australia;Bulgaria;Chile;China;Colombia;Denmark;France;Georgia;Germany;Greece;Ireland;Israel;Italy;Japan;Jordan;Korea, Republic of;Mexico;New Zealand;Norway;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Tunisia;Turkey;United Kingdom;United States
Eltrombopag
Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan
2016 Phase 3 NCT02877212 Pakistan
Eisai Inc.
2012 Phase 3 NCT01433978 United States
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline
2012 Phase 3 NCT01520909 Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2010 - NCT01439321 -
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2009 - NCT01236014 -
2009 Phase 2 NCT00908037 Canada;France;Netherlands;Spain;United Kingdom;United States
2007 Phase 2 NCT00424177 Australia;Canada;Germany;India;Korea, Republic of;Netherlands;Russian Federation;Spain;Tunisia;United Kingdom;United States
2006 Phase 3 NCT00370331 Austria;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 Phase 2 NCT02402998 Italy
2016 - NCT02298075 Italy
Humanity & Health Medical Group Limited
2018 Phase 2 NCT03830749 Hong Kong
Ingrid Pabinger, MD
2009 Phase 4 NCT00888901 Austria
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 4 NCT05583838 China
Jikei University school of Medicine
2011 - JPRN-UMIN000006150 Japan
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Nayera Hazaa Elsherif
2018 - NCT03412188 Egypt
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
Novartis Pharmaceuticals
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2018 Phase 2 NCT03524612 Austria;Brazil;Chile;France;Greece;Italy;Japan;Mexico;Oman;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
2010 - NCT01416311 -
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2020 - NCT04214951 China
The First Affiliated Hospital, College of Medicine, Zhejiang University
2022 Phase 4 ChiCTR2000040991 China
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
University Hospital, Macau
2015 - ChiCTR1900021211 China
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
Yunfeng Cheng
2024 - NCT06479291 China;Hong Kong;Macau
Eltrombopag 25 MG
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
Eltrombopag and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2012 Phase 2 NCT01652599 Mexico
Eltrombopag and romiplastim
Assiut University
2023 - NCT06137105 -
Eltrombopag combining rituximab
Institute of Hematology & Blood Diseases Hospital
2020 Phase 4 NCT04518475 China
Eltrombopag olamine
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
Eltrombopag olamine, revolade, promacta
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Eltrombopag oral tablets
GlaxoSmithKline
2008 Phase 3 NCT00828750 Japan
Eltrombopag plus diacerein
Qilu Hospital of Shandong University
2020 Phase 2 NCT04917679 China
ESG206
Shanghai Escugen Biotechnology Co., Ltd
2025 Phase 1/Phase 2 NCT06853444 China
Estimation OF serum level OF IL17
Sohag University
2022 - NCT05371743 Egypt
Estimation OF serum level OF IL2
Sohag University
2022 - NCT05371743 Egypt
Ethanolamine
West China Hospital,Sichuan University
2022 Phase 2 ChiCTR2200065074 China
Fecal microbiota transplantation
Chinese University of Hong Kong
2019 - NCT04014413 Hong Kong
Fostamatinib
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2023 - NCT06071520 Spain
Kissei Pharmaceutical Co., Ltd.
2023 - NCT06757257 Japan
2019 Phase 3 JPRN-jRCT2080224916 Japan
Fostamatinib disodium
Rigel Pharmaceuticals
2015 Phase 3 NCT02076412 Austria;Bulgaria;Czech Republic;Czechia;Germany;Norway;Poland;Romania;Spain;United States
2014 Phase 3 NCT02077192 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Hungary;Italy;Netherlands;Norway;Poland;Romania;Spain;United Kingdom;United States
2014 Phase 3 NCT02076399 Australia;Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Fostamatinib disodium / R935788
Rigel Pharmaceuticals
2007 Phase 2 NCT00706342 United States
Fostamatinib disodium 100 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium 150 MG
Rigel Pharmaceuticals
2018 - NCT03363334 -
Fostamatinib disodium tablets
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Gammaplex
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Gammaplex, intravenous immunoglobulin
Bio Products Laboratory
2007 Phase 3 NCT00504075 Argentina;India;United States
Global DNA methylation will BE quantified IN THE DNA samples BY colorimetry
Assiut University
2019 - NCT04100876 -
Glycyrrhetinic acid
Shandong University
2019 Phase 4 NCT03998982 China
Glycyrrhiza
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
GMA161
Genzyme, a Sanofi Company
2005 Phase 1 NCT00244257 United States
GNR-069
AO GENERIUM
2022 Phase 3 NCT05492409 Russian Federation
2021 Phase 3 NCT05220878 Russian Federation
H. pylori triple therapy
Federal University of São Paulo
2008 Phase 2/Phase 3 NCT01730352 Brazil
HBM9161 dose A
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
HBM9161 dose B
Harbour BioMed (Guangzhou) Co. Ltd.
2020 Phase 2/Phase 3 NCT04428255 China
Healthy controls
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Herombopag
Jiangsu HengRui Medicine Co., Ltd.
2023 Phase 3 NCT05685420 -
Herombopag olamine tablets
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 2 NCT06838949 China
Hetrombopag
Jiangsu HengRui Medicine Co., Ltd.
2021 Phase 3 NCT04737850 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
West China Hospital, Sichuan University
2025 - ChiCTR2500096457 China
Wuhan Union Hospital, China
2022 - NCT05333861 China
Hetrombopag 5MG PO QD
Shandong University
2023 Phase 2 NCT05943691 China
Hetrombopag olamine
Jiangsu HengRui Medicine Co., Ltd.
2015 Phase 1 NCT02614846 China
2014 Phase 1 NCT02403440 China
High dose dexamethasone pulses
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
HIGH-dose dexamethasone
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Shandong University
2023 Phase 2 NCT05943691 China
The First Affiliated Hospital of Xi'an Jiaotong University
2024 - ChiCTR2500095505 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
Higher dose OF rituximab
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
HMPL-523
Hutchison Medipharma Limited
2021 Phase 3 NCT05029635 China
Hutchmed
2024 Phase 1 NCT06291415 Australia;Germany;Norway;Spain;United States
Huaiqihuang granule
Qidong Gaitianli Medicines Co., Ltd
2017 Phase 4 NCT03201848 China
Human immunoglobulin
LFB BIOTECHNOLOGIES
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Octapharma AG
2007 Phase 3 EUCTR2005-003552-35-FR Austria;Czech Republic;France;Germany
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Human immunoglobulin G
Octapharma AG
2006 - EUCTR2005-003552-35-DE Czech Republic;France;Germany
2006 - EUCTR2005-003552-35-AT Austria;Czech Republic;France;Germany
Human normal immunoglobulin
Bio Products Laboratory Limited
- - EUCTR2011-005586-21-Outside-EU/EEA Argentina;India;United States
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Human normal immunoglobulin FOR intravenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Human normal immunoglobulin FOR intrvenous USE
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Humax-CD38
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-FR Denmark;France;Norway
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
2020 Phase 2 EUCTR2019-004683-22-NO Denmark;Norway
Hydroxychloroquine
Jinshan Hospital, Fudan University
2020 Phase 4 ChiCTR2100045747 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
Hydroxychloroquine oral tablet
Yunfeng Cheng
2024 - NCT06479317 China;Hong Kong;Macau
2024 - NCT06479304 China;Hong Kong;Macau
2024 - NCT06479291 China;Hong Kong;Macau
Hypersialylated immunoglobulin
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
I10E
LFB BIOTECHNOLOGIES
2012 Phase 3 EUCTR2011-001354-29-ES Belarus;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-IT Germany;Hungary;Italy;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-HU France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
2011 - EUCTR2011-001354-29-DE France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;Ukraine
Ianalumab
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharmaceuticals
2023 Phase 2 NCT05885555 Argentina;Australia;China;Czechia;France;Germany;Italy;Korea, Republic of;Malaysia;Poland;Spain;Turkey;United Kingdom;United States
2023 Phase 3 NCT05653349 Argentina;Australia;Austria;Belgium;Bulgaria;China;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
2023 Phase 3 NCT05653219 Argentina;Australia;Austria;Belgium;China;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Yamauchi Kyosuke
2023 Phase 3 JPRN-jRCT2061220095 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;China;Czech Republic;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Vietnam
2023 Phase 3 JPRN-jRCT2031220623 Japan;Singapore
IG vena 100 ML vial
Kedrion SpA
2013 - EUCTR2013-000961-36-IT Italy
IG vena 50 G/L solution FOR infusion 100 ML vial + infusion SET
Kedrion SpA
2013 Phase 3 EUCTR2013-000961-36-DE Germany;Italy
IGG next generation
Biotest AG
2018 Phase 3 EUCTR2015-003653-17-CZ Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-DE Bulgaria;Czech Republic;Germany;Hungary;Spain
2017 Phase 3 EUCTR2015-003653-17-BG Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-HU Bulgaria;Czech Republic;Germany;Hungary;Spain
2016 Phase 3 EUCTR2015-003653-17-ES Bulgaria;Czech Republic;Germany;Hungary;Spain
IGIV3I grifols
Grifols Biologicals Inc.
2008 Phase 3 NCT00511147 Canada;India;Puerto Rico;United States
Instituto Grifols, S.A.
2008 Phase 3 NCT00699140 Russian Federation;Spain;United Kingdom
Igpro10
CSL Behring
2011 Phase 4 NCT01390649 Bulgaria;Poland;Romania;Serbia
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
ZLB Behring AG
2004 - EUCTR2004-000537-11-DE Germany;Italy
Immune globulin intravenous
Baxalta now part of Shire
2002 Phase 3 NCT00157079 United States
Immune globulin intravenous (human), 10% triple virally reduced solution
Baxalta now part of Shire
2003 Phase 2 NCT00162006 Czech Republic;Czechia;Germany;Hungary;Poland
Immunglobulin
Octapharma AG
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulin
CSL Behring
2004 Phase 3 NCT00168038 Germany;Italy;Poland;Russian Federation;Switzerland;Ukraine;United Kingdom
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Immunoglobulin G
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
OCTAPHARMA AG
2012 - EUCTR2012-000796-16-PL Bulgaria;Czech Republic;Poland
2012 - EUCTR2012-000796-16-DE Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-CZ Bulgaria;Czech Republic;Germany;Poland
2012 - EUCTR2012-000796-16-BG Bulgaria;Czech Republic;Poland
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Immunoglobulina umana normale
ZLB BEHRING
2005 - EUCTR2004-000537-11-IT Germany;Italy
Inactivated trivalent influenza vaccine
Neufeld, Ellis J, MD, PhD
2004 - NCT01713855 United States
Interleukin 2
Assistance Publique - Hôpitaux de Paris
2014 Phase 2 NCT01988506 France
Intravenous immunoglobulin (ivig), 10% solution FOR infusion
Biopharma Plasma LLC
2022 Phase 3 NCT05422365 Ukraine
Ivig
Momenta Pharmaceuticals, Inc.
2018 Phase 1/Phase 2 NCT03866577 Belgium;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United States
Ivig infusion
McMaster University
2012 Phase 3 NCT01621204 Canada;Netherlands
IVIG-L
Sanquin
2001 Phase 3 NCT00151840 Poland
L01fc01
Ostfold Hospital Trust
2022 Phase 2 EUCTR2019-004683-22-DK Denmark;France;Norway
Lansoprazole, clarithromycin, amoxycillin
Mahidol University
2006 Phase 4 NCT00467571 Thailand
LGD-4665
GlaxoSmithKline
2008 Phase 2 NCT00621894 United States
LIV-gamma SN INJ.
SK Plasma Co., Ltd.
2019 Phase 3 NCT05566990 Korea, Republic of
Lusutrombopag
Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
2024 Phase 4 ChiCTR2400080388 China
Lusutrombopag oral tablet
Institute of Hematology & Blood Diseases Hospital, China
2024 Phase 2 NCT06287567 China
M254
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
Mabthera
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2010 Phase 3 EUCTR2005-005918-20-GB France;Sweden;United Kingdom
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
University Hospital, Toulouse
2009 - NCT00960713 France
MabthéRA
Assistance Publique - Hôpitaux de Paris
2003 Phase 2 NCT00225875 France
Medical standard OF care FOR ITP
Amgen
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
Methylprednisolone
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
2016 Phase 4 study ChiCTR-IIR-16008994 China
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Methylprednisolone and ivig
The Hospital for Sick Children
2005 Phase 3 NCT00376077 Canada
Metilprednisolone
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Metronidazole
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Mezagitamab
Takeda
2025 Phase 3 NCT06948318 -
2025 Phase 3 NCT06722235 China;Japan
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Montelukast
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Mycophenolate mofetil
The First Affiliated Hospital of Dalian Medical University
2014 - ChiCTR-TRC-14004514 China
Nanogam
University Medical Center Utrecht
2009 Phase 3 EUCTR2008-001597-33-NL Netherlands
Neofordex
Sykehuset Østfold HF
2017 Phase 3 EUCTR2015-005276-14-FR Denmark;France;Morocco;Norway;Tunisia;United Kingdom
Newgam
Octapharma
2011 Phase 3 NCT01349790 Germany
Octapharma AG
2013 Phase 3 EUCTR2009-014589-24-FR Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2012 - EUCTR2009-014589-24-BG Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-DE Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
2011 - EUCTR2009-014589-24-CZ Bulgaria;Czech Republic;France;Germany;India;Poland;Romania;Russian Federation;Ukraine
Nicotinamide adenine dinucleotid/nicotinamide mononucleotide
Institute of Hematology & Blood Diseases Hospital, China
2025 Phase 1/Phase 2 NCT06776510 China
NK cells
Changzhou No.2 People's Hospital
2024 Early Phase 1 NCT06337474 China
Nplate
AO GENERIUM
2021 Phase 3 NCT05220878 Russian Federation
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
Nplate 500 microgramos polvo para solucióN inyectable
Amgen Inc
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
Obinutuzumab
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 2 NCT06094881 China
2023 Phase 2 NCT05995054 China
Orelabrutinib
Beijing InnoCare Pharma Tech Co., Ltd.
2023 Phase 3 NCT06004856 China
2022 Phase 2 NCT05232149 China
Shandong University
2021 Phase 2 NCT05020288 -
Paracetamolo
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
PF-06755347 intravenous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous healthy participant
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06755347 subcutaneous ITP
Pfizer
2017 Phase 1 NCT03275740 Belgium;New Zealand;Spain;United Kingdom;United States
PF-06835375
Pfizer
2022 Phase 2 NCT05070845 Australia;Canada;Czechia;Hungary;Poland;United Kingdom;United States
Pfizer Inc.
2022 Phase 2 EUCTR2021-002897-19-HU Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
2022 Phase 2 EUCTR2021-002897-19-CZ Australia;Canada;Czech Republic;Czechia;Hungary;Poland;United States
PG2
PhytoHealth Corporation
2008 Phase 2 NCT00860600 Taiwan
Plasma RNA isolation, qpcr analysis OF micro RNA
Sohag University
2022 - NCT05371743 Egypt
PN20
Chongqing Peg-Bio Biopharm Co., Ltd.
2022 Phase 1 NCT06523088 China
PN20 treatment
Chongqing Peg-Bio Biopharm Co., Ltd.
2025 Phase 1 NCT06880081 China
Povetacicept
Alpine Immune Sciences, Inc.
2023 Phase 1/Phase 2 NCT05757570 Australia;Austria;Canada;Germany;Italy;Norway;Spain;Turkey;United Kingdom;United States
Prednisolone
Cooperative Study Group A for Hematology
2005 Phase 3 NCT00451594 Korea, Republic of
Renata PLC
2025 Phase 1/Phase 2 NCT06531018 Bangladesh
Prednisone
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
2013 - ChiCTR-TRC-13003602 China
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
2008 - EUCTR2008-000417-30-IT Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
Huizhou Municipal Central Hospital
2022 Phase 4 ChiCTR2100053452 China
Isfahan University of Medical Sciences
2016 Phase 2/Phase 3 NCT02914054 Iran, Islamic Republic of
Mayo Clinic
2007 Phase 0 NCT00486421 United States
New England Research Institutes
2010 Phase 3 NCT00991939 United States
Shandong University
2010 Phase 4 NCT01356511 China
The Second Affiliated Hospital of Guangxi Medical University
2023 Phase 4 ChiCTR2100053604 China
The Second Affiliated Hospital of Kunming Medical University
2023 Phase 4 ChiCTR2300068387 China
Prednisone acetate
Nanjing Drum Tower Hospital
2021 Phase 0 ChiCTR2300070251 China
Prednisone tablet
Yunfeng Cheng
2024 - NCT06479304 China;Hong Kong;Macau
Privigen
CSL Behring GmbH
2011 - EUCTR2011-000263-27-BG Bulgaria;Poland;Serbia;Turkey
CSL Behring LLC
2011 - EUCTR2011-000263-27-PL Bulgaria;Poland;Serbia;Turkey
Momenta Pharmaceuticals, Inc.
2019 Phase 1;Phase 2 EUCTR2018-003534-32-PL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-NL Belgium;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-HU Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
2019 Phase 1;Phase 2 EUCTR2018-003534-32-ES Belgium;France;Hungary;Italy;Netherlands;Poland;Spain;United States
PRN1008
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
PRN1008 100 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 300 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
PRN1008 400 MG tablet
Principia Biopharma Inc.
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NO Australia;Bulgaria;Canada;Czech Republic;Netherlands;Norway;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
ProteíNA recombinante estimulante DE LA megacariopoyesis
Amgen Inc.
2007 Phase 2 EUCTR2007-003569-42-ES Spain
Proton pump inhibitor 1 MG/KG/DAY IN 2 divided doses 1 month
Assiut University
2020 Phase 4 NCT03172676 Egypt
PRTX-100
Protalex, Inc.
2007 Phase 1 NCT00571467 Australia;New Zealand
QL0911
Qilu Pharmaceutical Co., Ltd.
2019 Phase 3 NCT05621330 China
Quality-OF-life assessment
Gruppo Italiano Malattie EMatologiche dell'Adulto
2008 Phase 3 NCT00657410 Italy
R788
Kissei Pharmaceutical Co., Ltd.
2019 Phase 3 NCT04132050 Japan
R935788
Rigel Pharmaceuticals, Inc.
2015 Phase 3 EUCTR2013-005454-30-PL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-IT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-HU Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005454-30-ES Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2015 Phase 3 EUCTR2013-005453-76-ES Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2015 Phase 3 EUCTR2013-005452-15-HU Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-NL Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-GB Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-DK Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-CZ Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-BG Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005454-30-AT Austria;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2014 Phase 3 EUCTR2013-005453-76-PL Austria;Bulgaria;Czech Republic;France;Germany;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-CZ Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-BG Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005453-76-AT Austria;Bulgaria;Czech Republic;Poland;Spain
2014 Phase 3 EUCTR2013-005452-15-NL Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-IT Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-GB Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
2014 Phase 3 EUCTR2013-005452-15-DK Canada;Denmark;Hungary;Italy;Netherlands;United Kingdom;United States
Rapamycin
First Affiliated Hospital of Suzhou Medical College
2011 - NCT01672151 China
Recombinant human thrombopoietin
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Peking University People's Hospital
2020 - NCT04214951 China
Shandong University
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Relovade
GlaxoSmithKline Research and Development Ltd
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
Revolade
Fondazione G.I.M.EM.A. Gruppo Italiano Malattie Ematologiche dell'Adulto
2015 Phase 2 EUCTR2015-001327-23-IT Italy
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Revolade 25 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade 50 MG FILM-coated tablets
Eisai Limited
2012 - EUCTR2011-000831-10-NL Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-GB Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-ES Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-DE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 Phase 3 EUCTR2011-000831-10-BE Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
2012 - EUCTR2011-000831-10-AT Australia;Austria;Belgium;Canada;France;Germany;Ireland;Israel;Italy;Korea, Republic of;Netherlands;Russian Federation;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States
Revolade, promacta
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Rhtpo
Department of Hematology, Anhui Provincial Hospital
2020 Phase 4 ChiCTR1900027735 China
Department of Hematology, Second Medical Center, Chinese PLA General Hospital
2021 Phase 2 ChiCTR2000039630 China
Institute of Hematology & Blood Diseases Hospital, China
2022 Phase 4 NCT05583838 China
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
Peking Union Medical College
2011 Phase 3 NCT01805648 China
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Shandong University
2014 Phase 3 NCT02139501 China
2012 Phase 3 NCT01734057 China
2012 Phase 3 NCT01734044 China
2011 Phase 3 NCT01525836 China
Wuhan Union Hospital, China
2019 Phase 4 NCT03771378 China
Rhtpo IN combination with rituximab
Ming Hou
2009 Phase 3 NCT01506414 China
Rilzabrutinib
Principia Biopharma Inc.
2020 Phase 3 EUCTR2020-002063-60-IT Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, Inc.
2021 Phase 3 EUCTR2020-002063-60-NO Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-HU Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-FR Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czech Republic;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2020-002063-60-AT Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2020-002063-60-DE Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Türkiye;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-PL Argentina;Australia;Austria;Brazil;Canada;Chile;China;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
- Phase 3 EUCTR2020-002063-60-GB Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Norway;Poland;Russian Federation;Singapore;Spain;Thailand;Turkey;Ukraine;United Kingdom;United States
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 2 NCT03395210 Australia;Bulgaria;Canada;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
Rituxan
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
New York Medical College
2021 Phase 1 NCT04323748 United States
University Hospital, Toulouse
2009 - NCT00960713 France
Rituxan, cyclophosphamide, vincristine, prednisone
Weill Medical College of Cornell University
2003 Phase 2/Phase 3 NCT00774202 United States
Rituximab
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Department of Hematology, the Second Affiliated Hospital of Kunming Medical University
2020 Phase 4 ChiCTR1900027748 China
Hamilton Health Sciences Corporation
2006 Phase 2 NCT00372892 Canada
Henan Cancer Hospital
2020 Phase 4 ChiCTR2000035408 China
Hoffmann-La Roche
2007 Phase 2 NCT00475423 Australia
2005 Phase 3 NCT00770562 Italy
Institute of Hematology & Blood Diseases Hospital, China
2012 - NCT01719692 China
Keio University School of Medicine , Yoshitaka miyakawa
2011 Phase 3 JPRN-jRCT1091220070 Japan
Mayo Clinic
2007 Phase 0 NCT00486421 United States
Neufeld, Ellis J, MD, PhD
2003 Phase 1/Phase 2 NCT01713738 United States
ROCHE
2005 - EUCTR2005-000859-15-IT Italy
Rikshospitalet
2008 Phase 3 EUCTR2005-005918-20-FR France;Sweden;United Kingdom
Shandong University
2018 Phase 3 NCT03443570 China
2012 Phase 3 NCT01734057 China
2011 Phase 3 NCT01525836 China
2010 Phase 4 NCT03258866 China
Sykehuset Østfold HF
2016 Phase 3 EUCTR2015-005276-14-NO Denmark;Egypt;France;Norway;Tunisia
2016 Phase 3 EUCTR2015-005276-14-DK Denmark;Egypt;France;Norway;Tunisia
Sykehuset Østfold, Fredrikstad
2009 Phase 3 EUCTR2005-005918-20-SE France;Sweden;United Kingdom
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
2021 Phase 4 ChiCTR2100051890 China
2020 Phase 4 ChiCTR2000030603 China
University Hospital, Toulouse
2009 - NCT00960713 France
University of Alabama at Birmingham
2000 Phase 2 NCT00005652 United States
Weill Medical College of Cornell University
2004 Phase 2 NCT00161564 United States
Rituximab and dexamethasone
Hospital Universitario Dr. Jose E. Gonzalez
2010 Phase 2 NCT01107951 Mexico
Romiplostim
Amgen
2012 Phase 3 NCT01444417 Australia;Canada;United States
2010 Phase 2 NCT01143038 Australia;Czech Republic;Czechia;France;Germany;Italy;Poland;Spain;United Kingdom;United States
2009 Phase 3 NCT01071954 Australia;Canada;Spain;United States
2009 Phase 4 NCT00907478 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;United States
2006 Phase 3 NCT00415532 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States
2005 Phase 3 NCT00508820 Australia;Austria;Belgium;Canada;Czech Republic;Ireland;Italy;Netherlands;Poland;Slovakia;Spain;Switzerland;United Kingdom;United States
2004 Phase 3 NCT00116688 Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States
2002 Phase 1/Phase 2 NCT00117143 -
2002 Phase 2 NCT00111475 -
Amgen Inc
2013 Phase 2 EUCTR2010-019987-35-FR Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-IT Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 Phase 2 EUCTR2010-019987-35-GB Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 2 EUCTR2010-019987-35-ES Czech Republic;France;Germany;Italy;Spain;United Kingdom
2010 - EUCTR2010-019987-35-DE Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 - EUCTR2010-019987-35-CZ Czech Republic;France;Germany;Italy;Spain;United Kingdom;United States
2010 Phase 4 EUCTR2008-004347-10-BG Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SI Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-SE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-ES Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 Phase 4 EUCTR2008-004347-10-BE Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2009 - EUCTR2008-004347-10-AT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
Amgen Inc.
2009 - EUCTR2008-004347-10-IT Austria;Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Lithuania;Poland;Slovenia;Spain;Sweden
2008 Phase 2 EUCTR2007-000638-37-SK Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Slovakia;Spain;United Kingdom
2008 - EUCTR2007-000638-37-NL Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-GB Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-ES Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-CZ Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-BE Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
2008 - EUCTR2007-000638-37-AT Austria;Belgium;Czech Republic;Ireland;Italy;Netherlands;Spain;United Kingdom
FISEVI - Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla
2023 Phase 3 EUCTR2021-006970-22-IT Italy;Spain;United Kingdom
GlaxoSmithKline
2010 - NCT01439321 -
2009 - NCT01236014 -
Qilu Hospital of Shandong University
2024 Phase 4 ChiCTR2400091685 China
University Hospital, Basel, Switzerland
2016 Phase 4 NCT02760251 Switzerland
Weill Medical College of Cornell University
2009 Phase 2 NCT00902018 United States
Romiplostim plus dexamethasone
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2022 Phase 3 NCT05325593 Spain
Romiplostin
Gruppo Italiano Malattie EMatologiche dell'Adulto
2016 - NCT02298075 Italy
Rozanolixizumab
Sugihara Kazuhiro
2021 Phase 3 JPRN-jRCT2031210245 Austria;Belgium;Bulgaria;Canada;China;Croatia;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea;Poland;Republic of Moldova;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Biopharma SRL
2021 Phase 3 NCT04596995 China;Georgia;Germany;Hungary;Italy;Japan;Moldova, Republic of;Poland;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04224688 Austria;Belgium;Bulgaria;Canada;China;Czechia;Denmark;France;Germany;Hong Kong;Italy;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 NCT04200456 Austria;Belgium;Bulgaria;Croatia;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
UCB Japan Co., Ltd.
2020 Phase 3 JPRN-jRCT2080225255 Asia except Japan;Europe;Japan;North America
SAR444671
Principia Biopharma, a Sanofi Company
2019 Phase 1;Phase 2 EUCTR2017-004012-19-NL Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
2018 Phase 1;Phase 2 EUCTR2017-004012-19-BG Australia;Bulgaria;Canada;Czech Republic;Czechia;Netherlands;Norway;United Kingdom;United States
SB-497115
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2011-002184-17-IT Argentina;Chile;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2011 - EUCTR2006-002946-13-NL France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-GB France;Netherlands;Spain;United Kingdom
2009 Phase 2 EUCTR2006-002946-13-FR France;Netherlands;Spain;United Kingdom
- - EUCTR2006-002946-13-Outside-EU/EEA Canada;United States
GlaxoSmithKline Research and Development Limited
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
GlaxoSmithKline Research and Development Ltd
2014 Phase 4 EUCTR2013-001371-20-PL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2014 - EUCTR2013-001371-20-NL Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-IE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-GR Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2013 Phase 4 EUCTR2013-001371-20-BE Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
GlaxoSmithKline S.A.
2009 Phase 2 EUCTR2006-002946-13-ES France;Netherlands;Spain;United Kingdom
GlaxoSmithKline, S.A.
2013 Phase 4 EUCTR2013-001371-20-ES Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Spain;Taiwan;Thailand;Tunisia;United States
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Glaxosmithkline Research and Development Ltd
2012 - EUCTR2011-002184-17-PL Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-GB Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 - EUCTR2011-002184-17-DE Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
2012 Phase 3 EUCTR2011-002184-17-CZ Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
Glaxosmithkline, S.A.
2012 Phase 3 EUCTR2011-002184-17-ES Argentina;Chile;Czech Republic;Germany;Hong Kong;Israel;Italy;Poland;Russian Federation;Spain;Taiwan;Thailand;United Kingdom;United States
SB-497115-GR
GLAXO SMITHKLINE
2006 - EUCTR2004-000367-98-IT Denmark;Estonia;Germany;Ireland;Italy;Latvia;Spain;Sweden
GLAXOSMITHKLINE R&D LTD
2007 - EUCTR2006-000471-14-IT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline Research and Development Limited
2007 - EUCTR2006-000470-78-IT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
Novartis Pharmaceuticals
2006 Phase 3 NCT00351468 Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;India;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
SB-497115-GR 12.5MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 25MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB-497115-GR 50 MG
GlaxoSmithKline
2007 Phase 3 NCT00540423 Japan
SB497115
GlaxoSmithKline
2010 - EUCTR2009-010421-39-HU Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-DE Czech Republic;France;Germany;Hungary;Italy
2010 - EUCTR2009-010421-39-CZ Czech Republic;France;Germany;Hungary;Italy
2005 Phase 2 NCT00102739 Australia;Brazil;Canada;Denmark;Estonia;France;Germany;Greece;Hong Kong;Hungary;Ireland;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Poland;Romania;Russian Federation;Slovenia;Spain;Sweden;Switzerland;Taiwan;Thailand;Tunisia;Turkey;Ukraine;United Kingdom;United States
GlaxoSmithKline Research & Development Limited
2010 Phase 4 EUCTR2009-010421-39-FR Czech Republic;France;Germany;Hungary;Italy
GlaxoSmithKline Research and Development Limited
2008 Phase 4 EUCTR2006-000471-14-IE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 2 EUCTR2006-002943-10-GB Germany;Spain;United Kingdom
2007 - EUCTR2006-002943-10-DE Germany;Spain;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-SK Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2007 - EUCTR2006-000471-14-GR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-FI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000471-14-DE Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-CZ Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 - EUCTR2006-000471-14-AT Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2007 Phase 3 EUCTR2006-000470-78-SK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2007 - EUCTR2006-000470-78-GR Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-DE Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2007 - EUCTR2006-000470-78-CZ Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000471-14-SI Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-SE Australia;Austria;Canada;China;Czech Republic;Denmark;Finland;France;Germany;Greece;Hong Kong;Ireland;Italy;Korea, Republic of;Netherlands;New Zealand;Pakistan;Peru;Poland;Romania;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Taiwan;Thailand;Tunisia;Ukraine;United Kingdom;United States;Vietnam
2006 - EUCTR2006-000471-14-NL Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 Phase 3 EUCTR2006-000471-14-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovakia;Slovenia;Spain;Sweden;United Kingdom
2006 - EUCTR2006-000470-78-NL Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-GB Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-FR Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Slovakia;Spain;United Kingdom
2006 - EUCTR2006-000470-78-FI Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-DK Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2006-000470-78-AT Austria;Czech Republic;Finland;France;Germany;Greece;Italy;Netherlands;Spain;United Kingdom
2006 - EUCTR2004-000367-98-DK Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-SE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-LV Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-IE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-GB Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 Phase 2 EUCTR2004-000367-98-ES Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-EE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
2005 - EUCTR2004-000367-98-DE Denmark;Estonia;Germany;Ireland;Latvia;Spain;Sweden;United Kingdom
GlaxoSmithKline S.A.
2006 - EUCTR2006-000471-14-ES Austria;Czech Republic;Denmark;Finland;France;Germany;Greece;Ireland;Italy;Netherlands;Slovenia;Spain;Sweden;United Kingdom
GlaxoSmithKline, S.A.
2007 Phase 2 EUCTR2006-002943-10-ES Germany;Spain;United Kingdom
2006 Phase 3 EUCTR2006-000470-78-ES Austria;Brazil;Canada;China;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;India;Italy;Netherlands;New Zealand;Peru;Poland;Russian Federation;Slovakia;Spain;Taiwan;Tunisia;United Kingdom;United States;Vietnam
Serum interleukin 10 level
Sohag University
2023 - NCT05835050 Egypt
Sirolimus
Children's Hospital of Philadelphia
2006 Phase 1/Phase 2 NCT00392951 United States
Department of Hematology, Xiniao Hospital
2017 - ChiCTR-ONC-17012126 China
SM101
SuppreMol GmbH
2010 Phase 1;Phase 2 EUCTR2009-014842-28-BE Belgium;Germany;Poland
SM101 20MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
SM101 5MG/ML
SuppreMol GmbH
2010 - EUCTR2009-014842-28-PL Belgium;Germany;Poland;Russian Federation;Ukraine
2010 - EUCTR2009-014842-28-DE Belgium;Germany;Poland;Russian Federation;Ukraine
Standard therapy (without eltrombopag): HD-DXM
University Children's Hospital Basel
2022 Phase 2 NCT04812483 Switzerland
Staphylococcal protein A
Protalex, Inc.
2007 Phase 1 NCT00571467 Australia;New Zealand
Steroids
Safaa AA Khaled
2019 - NCT04113915 -
STSA-1301 subcutaneous injection
Jiangsu BioJeTay Biotechnology Co., Ltd.
2025 Phase 1/Phase 2 NCT06929299 China
Staidson (Beijing) Biopharmaceuticals Co., Ltd
2023 Phase 1 NCT06148389 China
SYM001
Symphogen A/S
2010 Phase 2 EUCTR2007-006081-15-GB Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2010 Phase 2 EUCTR2007-006081-15-BE Belgium;Germany;Spain;United Kingdom
2008 Phase 2 NCT00718692 Belgium;Germany;India;Israel;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United Kingdom;United States
2008 - EUCTR2007-006081-15-ES Belgium;Germany;Spain;United Kingdom
2008 - EUCTR2007-006081-15-DE Belgium;Germany;Spain;United Kingdom
TAK-079
MILLENNIUM PHARMACEUTICALS, INC.
2020 Phase 2 EUCTR2019-004103-12-IT Bulgaria;Croatia;Germany;Greece;Italy;Slovenia;Spain;Ukraine;United States
Takeda
2020 Phase 2 NCT04278924 Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Takeda Development Center Americas, Inc. (Takeda)
2022 Phase 2 EUCTR2019-004103-12-GR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2021 Phase 2 EUCTR2019-004103-12-DE Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-SI Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-HR Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
2020 Phase 2 EUCTR2019-004103-12-BG Bulgaria;China;Croatia;Germany;Greece;Italy;Japan;Slovenia;Spain;Ukraine;United States
Telitacicept
The Second Affiliated Hospital of Kunming Medical University
2021 Phase 4 ChiCTR2100051890 China
Teriflunomide
Peking University People's Hospital
2023 Phase 2 NCT06176235 China
Thrombopoietin
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
TPO
Peking University People's Hospital
2020 - NCT04214951 China
Shenyang Sunshine Pharmaceutical Co., LTD.
2016 Phase 4 NCT04089267 China
TPO-RA
Institute of Hematology & Blood Diseases Hospital, China
2021 - NCT04890041 China
Shanghai Municipal Hospital of Traditional Chinese Medicine
2024 Phase 0 ChiCTR2400086350 China
TPO-RAS combining ANTI-CD 20 monoclonal antibody
Institute of Hematology & Blood Diseases Hospital, China
2023 Phase 4 NCT05718856 China
TQB3473 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2025 Phase 3 NCT06900920 China
Treatment : H. pylori eradication
Seoul National University Hospital
2017 Phase 3 NCT03177629 Korea, Republic of
Tretinoin
The First Affiliated Hospital of Xinjiang Medical University
2025 - ChiCTR2500099739 China
Triple therapy
Safaa AA Khaled
2019 - NCT04113915 -
Tysabri
Sahlgrenska University Hospital
2009 Phase 1;Phase 2 EUCTR2008-005871-92-SE Sweden
UCB7665
UCB Biopharma S.P.R.L.
2016 Phase 2 NCT02718716 Australia;Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SPRL
2017 Phase 2 EUCTR2015-003984-12-LT Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2017 Phase 2 EUCTR2015-003984-12-BG Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-PL Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-ES Australia;Belgium;Bulgaria;Czech Republic;France;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-DE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-CZ Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
2016 Phase 2 EUCTR2015-003984-12-BE Australia;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
UCB Biopharma SRL
2021 Phase 3 EUCTR2019-003451-11-DK Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-HR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000884-26-GR Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2021 Phase 3 EUCTR2019-000883-40-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-FR Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-ES Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Denmark;France;Germany;Hong Kong;Hungary;Italy;Japan;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-DE Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-CZ Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Greece;Hong Kong;Italy;Korea, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-BG Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-003451-11-AT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Hong Kong;Italy;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-PL Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-NL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-IT Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-HU Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-GB Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;Denmark;Finland;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-ES Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-CZ Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-BG Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000884-26-AT Austria;Belgium;Bulgaria;Croatia;Czech Republic;Czechia;France;Georgia;Greece;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-PL Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-HU Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-GB Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-CZ Austria;Belgium;Bulgaria;Canada;China;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Moldova, Republic of;Netherlands;Poland;Romania;Russian Federation;Spain;Taiwan;Ukraine;United Kingdom;United States
2020 Phase 3 EUCTR2019-000883-40-BG Austria;Belgium;Bulgaria;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Georgia;Germany;Greece;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States
2016 Phase 2 EUCTR2015-003984-12-IT Australia;Belgium;Bulgaria;Czech Republic;Czechia;France;Georgia;Germany;Italy;Lithuania;Moldova, Republic of;Poland;Romania;Spain;United Kingdom
VAY736
NOVARTIS PHARMA AG
2023 Phase 3 EUCTR2022-001672-34-IT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-IT Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Novartis Farmacéutica, S.A.
2023 Phase 3 EUCTR2022-001627-32-ES Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-ES Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
Novartis Pharma AG
2023 Phase 3 EUCTR2022-001672-34-RO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-NO Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-BG Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001672-34-AT Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2023 Phase 3 EUCTR2022-001627-32-RO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-NO Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-FR Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-DE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-BE Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
2023 Phase 3 EUCTR2022-001627-32-AT Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001672-34-HU Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Turkey;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-CZ Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001672-34-BE Argentina;Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Italy;Japan;Malaysia;Mexico;Norway;Romania;Singapore;Spain;Thailand;Türkiye;United Kingdom;United States;Viet Nam
2022 Phase 3 EUCTR2022-001627-32-NL Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-HU Argentina;Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Türkiye;United Kingdom;United States
2022 Phase 3 EUCTR2022-001627-32-CZ Australia;Austria;Belgium;China;Czech Republic;Czechia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Philippines;Romania;Singapore;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States
Veltuzumab
Gilead Sciences
2007 Phase 1/Phase 2 NCT00547066 United States
Vinblastine
Nanjing Drum Tower Hospital
2024 Phase 0 ChiCTR2400080036 China
VIT D
Mansoura University
2023 Early Phase 1 NCT06073925 -
VON willebrand factor
Chengqiang Jin
2025 Phase 1 ChiCTR2500095632 China
Vonoprazan
TAKEDA PHARMACEUTICAL COMPANY LTD.
2015 - JPRN-jRCT1080222951 -
Takeda
2015 - NCT03219723 Japan
Water
Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine
2016 - ChiCTR-INR-16009363 China
Zanubrutinib
He'nan Cancer Hospital
2022 Phase 4 ChiCTR2200060868 China
Peking University People's Hospital
2022 Phase 2 NCT05369377 China
2022 Phase 2 NCT05279872 China
The Second Affiliated Hospital of Kunming Medical University
2022 Phase 1 ChiCTR2200057058 China
Zuberitamab
Union hospital tongji medical college huazhong university of science and technology
2021 Phase 2 ChiCTR2100050513 China